CoChat

Mineral oil: safety and use as placebo in REDUCE-IT and other clinical studies

Open access

The DOI matches its Crossref record; 72 of the 77 references it cites were found in a registry or an index.

Abstract

Mineral oil is often used as a clinical trial placebo. Pharmaceutical-grade mineral oil consists of a mixture of saturated hydrocarbons, with a purity and chemical structure that differs substantially from food-grade or technical-/industrial-grade mineral oils. Interest in mineral oil was piqued by suggestions that a portion of the substantially positive results of the Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial (REDUCE-IT) might be attributable to the theoretical negative effects of mineral oil rather than being due to the clinical benefits of icosapent ethyl. The objective of this review was to explore possible mineral oil safety and efficacy effects and contextualize these findings in light of the REDUCE-IT conclusions. A literature search identified studies employing mineral oil placebos. Eighty studies were identified and relevant data extracted. Adverse events associated with mineral oil were generally gastrointestinal and consistent with use as a lubricant laxative. Changes in triglycerides, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, high-sensitivity C-reactive protein, and other biomarkers were inconsistent and generally not statistically significant, or clinically meaningful with mineral oil, as were changes in blood pressure. There was no consistent evidence that mineral oil in the amounts used in the REDUCE-IT or Effect of Vascepa on Progression of Coronary Atherosclerosis in Patients With Elevated Triglycerides on Statin Therapy (EVAPORATE) trials affects absorption of essential nutrients or drugs, including statins. These results were then considered alongside publicly available data from REDUCE-IT. Based on available evidence, mineral oil does not appear to impact medication absorption or efficacy, or related clinical outcomes, and, therefore, does not meaningfully affect study conclusions when used as a placebo at the quantities used in clinical trials.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/eurheartj/suaa117

Cites

72 of 72 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Mineral oil grade classifications.7,29,30 C, carbon atoms; CFR, Code of Federal Regulations; cGMP, Current Good Manufacturing Practices; FDA, United States Food and Drug Administration; Ph Eur, European Pharmacopoeia; USP-NF, United States Pharmacopoeia–National Formulary. Asterisks and arrows represent refinement/hydrogenation processing steps: removal of impurities such as aromatic compounds, unsaturated compounds, and nitrogen- or sulfur-containing compounds.
Figure 1 Mineral oil grade classifications.7,29,30 C, carbon atoms; CFR, Code of Federal Regulations; cGMP, Current Good Manufacturing Practices; FDA, United States Food and Drug Administration; Ph Eur, European Pharmacopoeia; USP-NF, United States Pharmacopoeia–National Formulary. Asterisks and arrows represent refinement/hydrogenation processing steps: removal of impurities such as aromatic compounds, unsaturated compounds, and nitrogen- or sulfur-containing compounds.CC BY-NC · PubMed Central
Figure 2 Time to key primary and key secondary composite endpoint for icosapent ethyl and placebo by low-density lipoprotein cholesterol (A and C) and hsCRP (B and D) increase or no change/decrease (intent-to-treat population). The icosapent ethyl and placebo groups were compared regarding increases and no change/decreases in low-density lipoprotein cholesterol or high-sensitivity C-reactive protein levels for key REDUCE-IT primary and key secondary composite endpoints. Changes in these biomarkers did not influence time to primary and key secondary endpoints. CI, confidence interval; hsCRP, high-sensitivity C-reactive protein; IPE, icosapent ethyl; ITT, intent-to-treat; LDL-C, low-density lipoprotein cholesterol. The primary end point was a composite of cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, coronary revascularization, or unstable angina. The key secondary end point was a composite of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke.
Figure 2 Time to key primary and key secondary composite endpoint for icosapent ethyl and placebo by low-density lipoprotein cholesterol (A and C) and hsCRP (B and D) increase or no change/decrease (intent-to-treat population). The icosapent ethyl and placebo groups were compared regarding increases and no change/decreases in low-density lipoprotein cholesterol or high-sensitivity C-reactive protein levels for key REDUCE-IT primary and key secondary composite endpoints. Changes in these biomarkers did not influence time to primary and key secondary endpoints. CI, confidence interval; hsCRP, high-sensitivity C-reactive protein; IPE, icosapent ethyl; ITT, intent-to-treat; LDL-C, low-density lipoprotein cholesterol. The primary end point was a composite of cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, coronary revascularization, or unstable angina. The key secondary end point was a composite of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke.CC BY-NC · PubMed Central
Figure 3 Overview of the low-density lipoprotein cholesterol percentage changes observed in statin-treated cohorts from recent (published since 2003) cardiovascular outcome trials and other long-term studies that reported at least two statin-treated low-density lipoprotein cholesterol measurements over time, along with a comparison to low-density lipoprotein cholesterol changes in the Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial (REDUCE-IT). All plots represent statin-only arms, as represented by placebo (p) or statin (r = rosuvastatin, s = simvastatin, a = atorvastatin) or +e (ezetimibe), depending on the study. 4D, Die Deutsche Diabetes Dialyse Studie; ACCELERATE, Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition With Evacetrapib in Patients at a High Risk for Vascular Outcomes; AIM-HIGH, Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglycerides: Impact on Global Health Outcomes; ASCOT, Anglo-Scandinavian Cardiovascular Outcomes Trial; AURORA, A Study to Evaluate the Use of Rosuvastatin in Subjects On Regular Haemodialysis: an Assessment of Survival and Cardiovascular Events; CANVAS, Canagliflozin Cardiovascular Assessment Study; CARDS, Collaborative Atorvastatin Diabetes Study; dalOUTCOMES, Effects of the Cholesterol Ester Transfer Protein Inhibitor Dalcetrapib in Patients with Recent Acute Coronary Syndrome; DEFINE, Determining the Efficacy and Tolerability of Cholesteryl Ester Transfer Protein (CETP) Inhibition with Anacetrapib; DESCARTES, Durable Effect of PCSK9 Antibody Compared with Placebo Study; EMPA-REG, Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes; ENHANCE, Effect of Ezetimibe Plus Simvastatin vs. Simvastatin Alone on Atherosclerosis in the Carotid Artery; EXSCEL, Exenatide Study of Cardiovascular Event Lowering; FIRST, Evaluation of Choline Fenofibrate (ABT-335) on Carotid Intima-Media Thickness (cIMT) in Subjects with Type IIb Dyslipidaemia with Residual Risk in Addition to Atorvastatin Therapy; FOURIER, Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk; HOPE-3, Heart Outcomes Prevention Evaluation-3; IDEAL, Incremental Decrease in End Points Through Aggressive Lipid-Lowering; ILLUMINATE, Investigation of Lipid Level Management to Understand Its Impact in Atherosclerotic Events; ILLUSTRATE, Investigation of Lipid Level Management Using Coronary Ultrasound to Assess Reduction of Atherosclerosis by CETP Inhibition and HDL Elevation; IMPROVE-IT, Improved Reduction of Outcomes: Vytorin Efficacy International Trial; IRIS, Insulin Resistance Intervention After Stroke; LEADER, Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results; LIPS, Lescol Intervention Prevention Study; ODYSSEY-COMBO-II, Efficacy and Safety of Alirocumab vs. Ezetimibe on Top of Statin in High Cardiovascular Risk Patients With Hypercholesterolaemia; ODYSSEY OUTCOMES: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab; OSLER-1, Open Label Study of Long Term Evaluation Against LDL-C Trial; PROVE-IT, Pravastatin or Atorvastatin Evaluation and Infection Therapy; RADIANCE, Rating Atherosclerotic Disease Change by Imaging With a New CETP Inhibitor; REVEAL, Randomized EValuation of the Effects of Anacetrapib Through Lipid-modification; SEAS, Simvastatin Ezetimibe in Aortic Stenosis; SHARP, Study of Heart and Renal Protection; SPARCL, Stroke Prevention by Aggressive Reduction in Cholesterol Levels; SPIRE, Studies of PCSK9 Inhibition and the Reduction of Vascular Events; TNT, Treating to New Targets.
Figure 3 Overview of the low-density lipoprotein cholesterol percentage changes observed in statin-treated cohorts from recent (published since 2003) cardiovascular outcome trials and other long-term studies that reported at least two statin-treated low-density lipoprotein cholesterol measurements over time, along with a comparison to low-density lipoprotein cholesterol changes in the Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial (REDUCE-IT). All plots represent statin-only arms, as represented by placebo (p) or statin (r = rosuvastatin, s = simvastatin, a = atorvastatin) or +e (ezetimibe), depending on the study. 4D, Die Deutsche Diabetes Dialyse Studie; ACCELERATE, Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition With Evacetrapib in Patients at a High Risk for Vascular Outcomes; AIM-HIGH, Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglycerides: Impact on Global Health Outcomes; ASCOT, Anglo-Scandinavian Cardiovascular Outcomes Trial; AURORA, A Study to Evaluate the Use of Rosuvastatin in Subjects On Regular Haemodialysis: an Assessment of Survival and Cardiovascular Events; CANVAS, Canagliflozin Cardiovascular Assessment Study; CARDS, Collaborative Atorvastatin Diabetes Study; dalOUTCOMES, Effects of the Cholesterol Ester Transfer Protein Inhibitor Dalcetrapib in Patients with Recent Acute Coronary Syndrome; DEFINE, Determining the Efficacy and Tolerability of Cholesteryl Ester Transfer Protein (CETP) Inhibition with Anacetrapib; DESCARTES, Durable Effect of PCSK9 Antibody Compared with Placebo Study; EMPA-REG, Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes; ENHANCE, Effect of Ezetimibe Plus Simvastatin vs. Simvastatin Alone on Atherosclerosis in the Carotid Artery; EXSCEL, Exenatide Study of Cardiovascular Event Lowering; FIRST, Evaluation of Choline Fenofibrate (ABT-335) on Carotid Intima-Media Thickness (cIMT) in Subjects with Type IIb Dyslipidaemia with Residual Risk in Addition to Atorvastatin Therapy; FOURIER, Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk; HOPE-3, Heart Outcomes Prevention Evaluation-3; IDEAL, Incremental Decrease in End Points Through Aggressive Lipid-Lowering; ILLUMINATE, Investigation of Lipid Level Management to Understand Its Impact in Atherosclerotic Events; ILLUSTRATE, Investigation of Lipid Level Management Using Coronary Ultrasound to Assess Reduction of Atherosclerosis by CETP Inhibition and HDL Elevation; IMPROVE-IT, Improved Reduction of Outcomes: Vytorin Efficacy International Trial; IRIS, Insulin Resistance Intervention After Stroke; LEADER, Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results; LIPS, Lescol Intervention Prevention Study; ODYSSEY-COMBO-II, Efficacy and Safety of Alirocumab vs. Ezetimibe on Top of Statin in High Cardiovascular Risk Patients With Hypercholesterolaemia; ODYSSEY OUTCOMES: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab; OSLER-1, Open Label Study of Long Term Evaluation Against LDL-C Trial; PROVE-IT, Pravastatin or Atorvastatin Evaluation and Infection Therapy; RADIANCE, Rating Atherosclerotic Disease Change by Imaging With a New CETP Inhibitor; REVEAL, Randomized EValuation of the Effects of Anacetrapib Through Lipid-modification; SEAS, Simvastatin Ezetimibe in Aortic Stenosis; SHARP, Study of Heart and Renal Protection; SPARCL, Stroke Prevention by Aggressive Reduction in Cholesterol Levels; SPIRE, Studies of PCSK9 Inhibition and the Reduction of Vascular Events; TNT, Treating to New Targets.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 72 references

Research works printed but not linked: 6

  1. 2009, Aguilar F, Charrondiere UR, Dusemund B, Galtier P, Gilbert J, Gott DM, Grilli S, Guertler R, Koenig J, Lambré C, Larsen J-C, Leblanc J-C, Mortensen A, Parent-Massin D, Pratt I, Rietjens IMCM, Stankovic I, Tobback P, Verguieva T, Woutersen RA. Scientific opinion on the use of high viscosity white mineral oils as a food additive, EFSA J, 7, 1387
  2. 2012, EFSA Panel on Contaminants in the Food Chain (CONTAM), EFSA J, 10, 2704
  3. Budoff, 2019, Annual Scientific Sessions of the American Heart Association
  4. Soares, 2009, Effects of conventional treatment of chronic functional constipation on total and segmental colonic and orocecal transit times, J Pediatr (Rio J), 85, 322
  5. Allain, 2009, Effects of fish oil on metabolic alterations induced by carbohydrate overfeeding in healthy volunteers [abstract 534], Diabetologia, 52(Suppl 1, S214
  6. Mejia-Montilla, 2018, Vitamin D supplementation and lipid profile in women with polycystic ovary syndrome and vitamin D deficiency], Med Reprod Embriol Clin, 5, 123

Cited by

See all 107

Metadata

Authors
Olshansky, B., Chung, M. K., Budoff, M. J., Philip, S., Jiao, L., Doyle, Jr., Copland, C., Giaquinto, A., Juliano, R. A., & Bhatt, D. L.
Affiliations
  • University of Iowa (US)
  • Cleveland Clinic (US)
  • The Lundquist Institute (US)
  • Amarin (United States) (US)
  • Amarin Pharma, Inc, Bridgewater, NJ, USA
  • Brigham and Women's Hospital (US)
Corresponding author
Olshansky, Brian
Venue
European Heart Journal Supplements
Published
2020-10-01
Volume
22
Issue
Supplement_J
Pages
J34-J48
ISSN
  • 1520-765X (ISSN-L)
  • 1554-2815
OpenAlex
W3092016772
Cited by
103
References
77
Citations by year
2026: 7 · 2025: 14 · 2024: 12 · 2023: 25 · 2022: 22 · 2021: 21 · 2020: 1
FWCI
10.91
Type
journal article
Language
en
Open access
Locations
  • European Heart Journal Supplements (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • eScholarship (California Digital Library) (submittedVersion)
Funders
Amarin Pharma, Inc
Topics
  • Health Sciences › Nursing › Nutrition and Dietetics › Fatty Acid Research and Health
  • Physical Sciences › Mathematics › Statistics and Probability › Statistical Methods in Clinical Trials
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
Keywords
mineral oil, placebo, icosapent ethyl, alkanes, drug absorption, statins, triglycerides, cardiovascular events, adverse events, coronary artery disease

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Mineral oil: safety and use as placebo in REDUCE-IT and other clinical studies. https://app.cochat.ai/papers/10.1093/eurheartj/suaa117
The paper
Olshansky, B., Chung, M. K., Budoff, M. J., Philip, S., Jiao, L., Doyle, Jr., Copland, C., Giaquinto, A., Juliano, R. A., & Bhatt, D. L. (2020). Mineral oil: safety and use as placebo in REDUCE-IT and other clinical studies. European Heart Journal Supplements. https://doi.org/10.1093/eurheartj/suaa117

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.